...decortication, lung-sparing surgery, UCLA mesothelioma, P/D surgery, MARS trial, mesothelioma surgery
.../ref> His advocacy for preserving the lung proved prescient: the 2011 MARS trial confirmed that EPP offered no survival benefit and potentially harmed patie
...
22 KB (2,911 words) - 04:00, 9 March 2026
...nd decortication (P/D) for malignant pleural mesothelioma including MARS 2 trial results, HITHOC protocols, patient selection criteria, complication rates,
...thelioma, lung-sparing surgery, extended pleurectomy decortication, MARS 2 trial, HITHOC, mesothelioma surgery, EPP vs P/D, macroscopic complete resection,
...
46 KB (6,095 words) - 14:53, 9 April 2026
...nd decortication (P/D) for malignant pleural mesothelioma including MARS 2 trial results, HITHOC protocols, patient selection criteria, complication rates,
...thelioma, lung-sparing surgery, extended pleurectomy decortication, MARS 2 trial, HITHOC, mesothelioma surgery, EPP vs P/D, macroscopic complete resection,
...
46 KB (6,095 words) - 22:21, 8 March 2026
...iative procedures, emerging techniques, and multimodal therapy with MARS 2 trial analysis.
...ioma, pleurectomy decortication, CRS HIPEC peritoneal mesothelioma, MARS 2 trial, mesothelioma surgical candidacy, trimodal therapy mesothelioma, pleurodesi
...
56 KB (7,332 words) - 09:56, 6 April 2026
...technique, survival data by subgroup, the Sugarbaker favorable triad, MARS trial results, complications, quality of life, multimodal protocols, recurrence p
...lioma, EPP surgery, EPP vs P/D, mesothelioma surgery, Sugarbaker EPP, MARS trial mesothelioma, trimodal therapy mesothelioma, EPP survival rates, EPP compli
...
49 KB (6,519 words) - 10:01, 6 April 2026
..., and [[Dr_Paul_Baas|Dr. Paul Baas's]] [[CheckMate_743_Trial|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref>[
| style="padding:10px;" | MARS trial published
...
20 KB (2,490 words) - 20:57, 20 February 2026
...and pembrolizumab plus chemotherapy. Five-year data from the CheckMate 743 trial, published in February 2026, confirmed that immunotherapy more than doubles
...trating a mean survival advantage of 7 months for P/D. However, the MARS 2 trial raised fundamental questions about the benefit of surgery at all, finding t
...
55 KB (6,918 words) - 12:35, 6 April 2026
..., and [[Dr_Paul_Baas|Dr. Paul Baas]]'s [[CheckMate_743_Trial|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref n
* '''Surgery evolved from radical to conservative''' — The 2011 MARS trial showed extrapleural pneumonectomy offered no survival benefit, validating D
...
38 KB (4,755 words) - 03:42, 9 March 2026
...nt paradigm shift 2020-2026: CheckMate 743, pembrolizumab approval, MARS 2 trial, CAR-T therapy
* [[Pleural Mesothelioma]] — Immunotherapy, MARS 2 trial, CAR-T cell therapy, and TTFields
...
23 KB (2,626 words) - 01:08, 6 April 2026
...hensive treatment guide including CheckMate 743 immunotherapy data, MARS 2 trial findings, CAR-T therapy, and current survival statistics.''<ref name="mlcpl
* Clinical trial eligibility
...
25 KB (3,138 words) - 20:56, 20 February 2026
...adding:15px;" | '''⚠️ Note on Current Practice:''' Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many
...tly today than during Dr. Sugarbaker's peak years. Following the 2011 MARS trial, many centers shifted toward lung-sparing pleurectomy with decortication (P
...
28 KB (3,556 words) - 10:12, 6 April 2026
...ths for chemotherapy only, with 3.6x more serious adverse events<ref name="mars-2" />
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''MARS 2 Surgery Outcomes'''
...
59 KB (7,425 words) - 01:11, 6 April 2026
...oma — diagnostic yield, staging accuracy, therapeutic procedures, MesoVATS trial results, port-site metastasis evidence, complication rates, MARS2 controver
...pleuroscopy, mesothelioma staging, port-site metastasis, SMART trial, PIT trial, HITHOC, thoracoscopic surgery mesothelioma
...
60 KB (7,800 words) - 22:21, 8 March 2026
The MAPS trial demonstrated that adding bevacizumab 15 mg/kg every 3 weeks extends median
...w-approved-treatment-for-mesothelioma-in-more-than-a-decade/ CheckMate 743 trial] established this combination as a breakthrough first-line option. Nivoluma
...
33 KB (3,904 words) - 20:57, 20 February 2026
...ize:1.2em; color:#e8f4f8;">of mesothelioma lawsuits settle before reaching trial verdict<ref>[https://dandell.com/mesothelioma-lawsuit/ Mesothelioma Lawsuit
| style="padding:12px;" | Judge/jury decision after trial
...
91 KB (11,214 words) - 15:25, 24 February 2026
...n combined with pemetrexed, established by the landmark Phase III EMPHACIS trial that demonstrated a median survival of 12.1 months with the combination ver
...l function and pain scales at both 1 and 6 months after surgery. The MARS2 trial (2024) found that surgery was associated with worse quality of life and hig
...
47 KB (6,190 words) - 04:06, 8 March 2026
* [[Trial Preference|Trial Preference]]
...othelioma makes expedited legal action essential. Many jurisdictions offer trial preference or expedited scheduling for terminally ill plaintiffs, and famil
...
216 KB (26,444 words) - 23:30, 23 January 2026
